Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Non-responders to neoadjuvant chemotherapy in pancreatic adenocarcinoma: Characteristics and outcomes.
Authors
Brendan Hagerty
Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Brendan Hagerty , Fatemeh Fekrmandi , Moshim Kukar , Leonid Cherkassky , Benjamin Calvo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 662)
DOI
10.1200/JCO.2024.42.3_suppl.662
Abstract #
662
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy followed by surgery versus upfront surgery in patients with borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.
First Author: Junho Kang
Poster
2021 ASCO Annual Meeting
Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.
First Author: Davendra Sohal
Poster
2021 Gastrointestinal Cancers Symposium
Long-term outcomes with neoadjuvant chemotherapy with or without stereotactic body radiation therapy in patients with borderline resectable and locally advanced pancreatic adenocarcinoma.
First Author: Colin Hill
Poster
2021 Gastrointestinal Cancers Symposium
Adjuvant therapy in patients with resected pancreatic adenocarcinoma: Analysis of treatment allocation patterns in a Canadian provincial institution.
First Author: Manik Chahal